These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 28956198)

  • 21. Inflammation in heart failure: pathophysiology and therapeutic strategies.
    Boulet J; Sridhar VS; Bouabdallaoui N; Tardif JC; White M
    Inflamm Res; 2024 May; 73(5):709-723. PubMed ID: 38546848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel Biomarkers of Heart Failure.
    Savic-Radojevic A; Pljesa-Ercegovac M; Matic M; Simic D; Radovanovic S; Simic T
    Adv Clin Chem; 2017; 79():93-152. PubMed ID: 28212715
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic targeting of innate immunity in the failing heart.
    Topkara VK; Evans S; Zhang W; Epelman S; Staloch L; Barger PM; Mann DL
    J Mol Cell Cardiol; 2011 Oct; 51(4):594-9. PubMed ID: 21074541
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mitophagy and heart failure.
    Shires SE; Gustafsson ÅB
    J Mol Med (Berl); 2015 Mar; 93(3):253-62. PubMed ID: 25609139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The possible role of oxidative stress in heart failure and the potential of antioxidant intervention.
    Korantzopoulos P; Galaris D; Papaioannides D; Siogas K
    Med Sci Monit; 2003 Jun; 9(6):RA120-5. PubMed ID: 12824962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased systemic inflammation and oxidative stress in patients with worsening congestive heart failure: improvement after short-term inotropic support.
    White M; Ducharme A; Ibrahim R; Whittom L; Lavoie J; Guertin MC; Racine N; He Y; Yao G; Rouleau JL; Schiffrin EL; Touyz RM
    Clin Sci (Lond); 2006 Apr; 110(4):483-9. PubMed ID: 16402915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Leukocyte iNOS is required for inflammation and pathological remodeling in ischemic heart failure.
    Kingery JR; Hamid T; Lewis RK; Ismahil MA; Bansal SS; Rokosh G; Townes TM; Ildstad ST; Jones SP; Prabhu SD
    Basic Res Cardiol; 2017 Mar; 112(2):19. PubMed ID: 28238121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update on the pharmacological management of congestive heart failure.
    Thomas B; Vagueiro MC
    Rev Port Cardiol; 1999 Jun; 18(6):619-25. PubMed ID: 10422459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Role of Mitochondrial Dysfunction in Heart Failure and Potential Therapeutic Targets.
    Banović MD; Ristić AD
    Curr Pharm Des; 2016; 22(31):4752-4762. PubMed ID: 27306092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardioprotective effects of baicalein on heart failure via modulation of Ca(2+) handling proteins in vivo and in vitro.
    Zhao F; Fu L; Yang W; Dong Y; Yang J; Sun S; Hou Y
    Life Sci; 2016 Jan; 145():213-23. PubMed ID: 26706290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heart Inflammation: Immune Cell Roles and Roads to the Heart.
    Carrillo-Salinas FJ; Ngwenyama N; Anastasiou M; Kaur K; Alcaide P
    Am J Pathol; 2019 Aug; 189(8):1482-1494. PubMed ID: 31108102
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic, Prognostic, and Therapeutic Value of Circulating miRNAs in Heart Failure Patients Associated with Oxidative Stress.
    Ali Sheikh MS; Salma U; Zhang B; Chen J; Zhuang J; Ping Z
    Oxid Med Cell Longev; 2016; 2016():5893064. PubMed ID: 27379177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mitochondrial centrality in heart failure.
    Marín-García J; Goldenthal MJ
    Heart Fail Rev; 2008 Jun; 13(2):137-50. PubMed ID: 18185992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inflammatory Biomarkers and Therapeutic Targets in Heart Failure.
    Papadimitriou L; Kalogeropoulos AP
    Curr Med Chem; 2015; 22(23):2716-26. PubMed ID: 25876745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Central Role for Monocyte-Platelet Interactions in Heart Failure.
    Glezeva N; Gilmer JF; Watson CJ; Ledwidge M
    J Cardiovasc Pharmacol Ther; 2016 May; 21(3):245-61. PubMed ID: 26519384
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The cellular and physiologic effects of beta blockers in heart failure.
    Sabbah HN
    Clin Cardiol; 1999 Oct; 22 Suppl 5():V16-20. PubMed ID: 10526699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting BNIP3 in inflammation-mediated heart failure: a novel concept in heart failure therapy.
    Fordjour PA; Wang L; Gao H; Li L; Wang Y; Nyagblordzro M; Agyemang K; Fan G
    Heart Fail Rev; 2016 Sep; 21(5):489-97. PubMed ID: 27112557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Humoral Immunity in Heart Failure.
    Sarkar A; Rafiq K
    Cardiovasc Hematol Disord Drug Targets; 2019; 19(1):14-18. PubMed ID: 29773070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulation of mitochondrial oxidative stress by β-arrestins in cultured human cardiac fibroblasts.
    Philip JL; Razzaque MA; Han M; Li J; Theccanat T; Xu X; Akhter SA
    Dis Model Mech; 2015 Dec; 8(12):1579-89. PubMed ID: 26449263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Translation of hemodynamic stress to sterile inflammation in the heart.
    Nakayama H; Otsu K
    Trends Endocrinol Metab; 2013 Nov; 24(11):546-53. PubMed ID: 23850260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.